// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Perception of Cardiovascular Disease in Female Health Care Workers and Urgent Opportunity Gaps for Health Promotion

Johannes Bargehr - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Gendered Social Determinants of Health and Risk of Major Adverse Outcomes in Atrial Fibrillation An Analysis From the ESC-EHRA Eurobservational Research Programme in Atrial Fibrillation General Long-Term Registry

Jonathan Houle - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Sex-Based Differences in Outcomes After Mitral Valve Repair for Severe Secondary Mitral Regurgitation

Francesco Nappi - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Mitral valve regurgitation

N/A

Assessing Disease Severity Using Machine-Learning of Baseline 12-Lead Ecg Parameters in Attr Cardiac Amyloidosis

Dominic Pimenta - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

ATTR amyloidosis

N/A

Accurate Detection of Acute Psychological Stress Events Using Single Lead ECG Data

Adrian Deery - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Anxiety

N/A

Validation of a Deep-Learning-Based Retinal Biomarker in the Prediction of Cardiovascular Disease Data From UK Biobank

Rachel M Tseng - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Accurate, Non-Invasive Monitoring of VO2 Max Using Wearable ECG Technology

Mark Lilburn - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Reproducibility of Use by Physicians and Patients of a Smart Stethoscope for Artificial-Intelligence Enhanced Diagnosis of Heart Failure

Akila Wickramathilaka - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Subphenotypes of Heart Failure With Reduced Ejection Fraction Based on Repeated Measurements of 4210 Circulating Proteins Are Driven by Protein Subsets Reflecting Different Biological Mechanisms

Teun B Petersen - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with reduced ejection fraction

N/A

Proteomic Pathways Across Ejection Fraction Categories in Heart Failure An Exscel Substudy

Anthony E Peters - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

Exenatide

Increased Body Mass Index/Obesity is Associated With Higher Mortality and Major Adverse Cardiac Events in Patients With Hypertrophic Obstructive Cardiomyopathy (HOCM) on a Long-Term Follow-Up - A Systematic Review and Meta-Analysis

Samuel Edusa - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypertrophic cardiomyopathy

N/A

Novel Identification Strategy to Increase Diversity in Heart Failure Clinical Trials

Susan C Gilchrist - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial

Maria A Pabon porras - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with reduced ejection fraction

omecamtiv mecarbil (IV)

Characteristics and In-Hospital Outcomes of Haemochromatosis in Heart Failure

Raheel Ahmed - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hemochromatosis

N/A

The Significance of Concealed Fasciculo-Ventricular Connections in His Bundle Pacing

Rehan Mahmud - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

stannous fluoride

Changes in Clinical Phenotype of Patients With ATTR Cardiac Amyloidosis During the Past 20 Years

Adam Ioannou - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

ATTR amyloidosis

N/A

Effect of Diabetes Mellitus on Clinical Phenotype and Cardiovascular Mortality in Non-Ischaemic Dilated Cardiomyopathy

Daniel J Hammersley - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Dilated cardiomyopathy

N/A

Natural History, Penotypes and Clinical Outcomes in Desmin Related Arrhythmogenic Cardiomyopathy

Francisco Jose Bermudez-Jimenez - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmogenic right ventricular cardiomyopathy

Dermatan sulfate

A Role for Targeted Colchicine Uptitration in Recurrent Pericarditis A Ten-Year Experience of Treatment Refractory Disease at a Specialist Referral Center

Claire J Peet - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Recurrent pericarditis

Colchicine

Seasonal Variation in In-Hospital Outcomes of Takotsubo-Syndrome-Related Admissions A National Inpatient Analysis, 2019

Rupak Desai - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Takotsubo cardiomyopathy

N/A

Copyright © 2026. QuantiNova All rights reserved